Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?

Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.

But while negative headlines about the UK opportunity mostly related to Brexit, may abound at the moment, those with an intimate knowledge of this vibrant sector are keen to point out that the UK is world-leading country in which to do business, and will in fact get better in coming years.